REGN9533

Phase 1Small molecule

Regeneron

REGN9533 is one of 4 small molecule programs targeting End-Stage Kidney Disease (ESKD). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

End-Stage Kidney Disease (ESKD)Not yet recruiting

End-Stage Kidney Disease (ESKD)Phase 1

Not yet recruiting

Competition

Competitive Landscape

3 competitors in End-Stage Kidney Disease (ESKD)

#DrugCompanyPhaseTrials

Heparin Sodium

BBaxter Healthcare Corporation

Phase 1

1 2

REGN9933

Regeneron

Phase 1

1 3

REGN7508

Regeneron

Phase 1

1 4

REGN9533

Regeneron

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

End-Stage Kidney Disease (ESKD)

NCT07759167

Clinical

Trials by Indication[1]

Phase 11 trial

Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults

Completed· Regeneron logo

Regeneron·Phase 1·NCT06665828·72 enrolled

End-Stage Kidney Disease (ESKD)1 trial

A Master Protocol for a Phase 1b Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 and REGN7508, Factor XI Monoclonal Antibodies, and REGN9533, a Factor XII Monoclonal Antibody, in Participants With End-Stage Kidney Disease on Hemodialysis

Not yet recruiting· Regeneron logo

Regeneron·Phase 1·NCT07759167·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for REGN9533. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGN9533 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGN9533. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Regeneron

REGN9533

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Phase 11 trial

End-Stage Kidney Disease (ESKD)1 trial

References

Drug Info

Quick Facts

Related News